A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study in Healthy Subjects and Multiple Dose Study of JNJ-55920839 in Subjects With Mild to Moderate Systemic Lupus Erythematosus
Phase of Trial: Phase I
Latest Information Update: 14 Dec 2017
At a glance
- Drugs JNJ 55920839 (Primary) ; JNJ 55920839 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 11 Dec 2017 Planned End Date changed from 19 Sep 2018 to 1 Sep 2018.
- 11 Dec 2017 Planned primary completion date changed from 22 Dec 2017 to 1 Sep 2018.
- 11 Dec 2017 Status changed from suspended to recruiting.